15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3.2B | $349M | 77.7% | 12.7% | $725M | $597M | $1.3B |
| 2024 | $2.9B | $427M | 79.7% | 17.0% | $487M | — | $943M |
| 2023 | $2.4B | $168M | 78.0% | 7.7% | $63M | — | $755M |
| 2022 | $2.1B | $142M | 76.0% | 7.7% | $55M | — | $725M |
| 2021 | $1.8B | -$64M | 74.5% | -4.5% | $209M | — | $587M |
| 2020 | $1.9B | $854M | 71.8% | -2.3% | -$29M | — | $649M |
| 2019 | $1.7B | -$24M | 78.9% | -5.9% | -$97M | — | $437M |
| 2018 | $1.5B | -$77M | 78.9% | -8.3% | -$124M | — | $494M |
| 2017 | $1.3B | -$117M | 81.6% | -1.1% | -$208M | — | $598M |
| 2016 | $1.1B | -$630M | 81.2% | -71.9% | -$376M | — | $408M |
| 2015 | — | -$172M | — | — | — | — | $397M |
| 2014 | — | -$134M | — | — | — | — | $875M |
| 2013 | — | -$176M | — | — | -$125M | — | $569M |
| 2012 | — | -$114M | — | — | -$27M | — | $181M |
| 2011 | — | -$54M | — | — | -$55M | — | $46M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $766M | $106M | 74.6% | 16.9% | $200M | $1.4B | $2.2B |
| Dec '25 | $875M | -$47M | 68.5% | -5.1% | $59M | $597M | $1.3B |
| Sep '25 | $776M | -$31M | 82.0% | -6.0% | $340M | — | $1.3B |
| Jun '25 | $825M | $241M | 81.8% | 33.5% | $168M | — | $1.2B |
| Mar '25 | $745M | $186M | 79.7% | 30.0% | $158M | — | $1.0B |
| Dec '24 | $747M | $125M | 81.8% | 21.6% | $166M | — | $943M |
| Sep '24 | $746M | $106M | 74.7% | 15.3% | $203M | — | $675M |
| Jun '24 | $712M | $107M | 81.7% | 16.9% | $97M | — | $972M |
| Mar '24 | $649M | $89M | 80.7% | 13.6% | $21M | — | $747M |
| Dec '23 | $646M | $20M | 78.7% | 4.2% | -$1M | — | $755M |
| Sep '23 | $581M | $40M | 78.0% | 5.3% | $114M | — | $785M |
| Jun '23 | $595M | $56M | 78.1% | 11.0% | $48M | — | $694M |
| Mar '23 | $596M | $51M | 77.3% | 10.5% | -$98M | — | $580M |
| Dec '22 | $538M | -$249000 | 76.3% | -4.6% | -$29M | — | $725M |
| Sep '22 | $505M | -$7M | 77.0% | -0.5% | $129M | — | $762M |
| Jun '22 | $534M | $28M | 76.9% | 7.3% | $29M | — | $620M |
| Mar '22 | $519M | $121M | 77.5% | 26.4% | -$74M | — | $605M |
| Dec '21 | $450M | -$58M | 73.4% | -14.6% | -$18M | — | $587M |
| Sep '21 | $409M | -$36M | 74.7% | -13.0% | $78M | — | $617M |
| Jun '21 | $502M | $13M | 74.7% | 2.3% | $60M | — | $642M |
How the market has priced BMRN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Biomarin Pharmaceutical Inc's revenue has grown 11.6% per year, and net income declined 16.4% per year. These are computed facts, not advice.
As of FY2025, Biomarin Pharmaceutical Inc reported $597M of total debt against $1.3B of cash; operating income covered interest expense 38×.
In FY2025, gross margin was 77.7%, operating margin 12.7%, and net margin 10.8%.
As of Jun '26, Biomarin Pharmaceutical Inc traded at a price-to-earnings ratio of about 31.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.